Over the YEARS, the Medical Post has taken politicians to task for ineffective handling of health reform. To give them some credit, many political issues are complex with no clear-cut solution.
The state and its players find themselves at the heart of a battle between generic companies and innovator drug makers. And the two pharmaceutical lobbies are using numbers to duke it out.
